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Multiple sclerosis and immune regulatory cells
The multiple sclerosis disease process is defined on the basis
of lesions disseminated in space and time within the CNS.
Immunization of humans (vaccines) and animals with neural
tissue can result in multi-focal CNS inflammatory lesions with
demyelination; such disorders are usually uniphasic or self-
limited. They are initiated by systemically activated myelin-
reactive T cells that then access the CNS. Myelin-reactive
T cells can be recovered from the CNS and blood in multiple
sclerosis. Such cells can also be recovered from unaffected
individuals. These observations raise issues regarding the
origin of such cells in non-immunized individuals and why
their presence is variably associated with uniphasic disease,
recurrent disease, or no disease. Most autoreactive cells may
actually be generated in response to exogenous peptide
antigens with which there is cross-reactivity (molecular
mimicry) with myelin antigens, reflecting the degeneracy
of antigen recognition by T-cell receptors (Nino-Vasquez
et al., 2004).
Studies in animals showing that depletion of specific
subpopulations of immune cells can unmask spontaneous
or antigen-induced autoimmune disease, or conversely that
such cells can transfer disease resistance, indicate that
active immune-regulatory mechanisms contribute to the dis-
connection between the presence of autoreactive T cells and
the development of autoimmune disease. As the capacity to
define subsets of immune cells has evolved, an increased
number of such subsets have been implicated as mediators
of immune regulation with different potential mechanisms of
action.
An initial ‘holy grail’ of immunology was to find a
regulatory (‘suppressor’) cell with properties equivalent to
the classic cytotoxic and helper cell members of the adaptive
immune system, namely cells that were both antigen and
major histocompatibility complex (MHC) restricted. Initial
studies focused on the CD8 T-cell subset which includes
both cytotoxic cells and ‘suppressor’ cells. The therapeutic
approach aimed at depleting disease-relevant antigen-specific
T cells by immunizing animals or multiple sclerosis patients
with myelin-reactive T cells or their receptors probably is
mediated via generation of CD8 cytotoxic T cells directed
at the autoreactive cells (Ben Nun et al., 1981). CD8 T cells
can also inhibit CD4 T-cell-dependent immunoglobulin
production in a non-cytotoxic manner; such functional
CD8-mediated suppression is decreased in multiple sclerosis
(Antel et al., 1984). In the experimental autoimmune
encephalitis (EAE) model, CD4 T-cell-mediated suppression
accounts for animals being refractory to recurrent disease
immediately after the initial exacerbation (Lenz and
Swanborg, 1999). CD4-mediated suppression can involve
production of anti-inflammatory (Th2/3) cytokines. More
recently, a functional derangement in a subset of suppressor
CD4 T cells, defined by the phenotype CD4þCD25þ and
acting via cell–cell-dependent mechanisms, was found to
correlate with disease activity in multiple sclerosis (Viglietta
et al., 2004).
Takahashi et al. (Brain, this issue) focus attention on
natural killer (NK) cells as suppressors of myelin basic
protein (MBP)-reactive T cells in multiple sclerosis patients.
Although NK cells lack the receptor diversity of T and B
cells, their array of surface receptors permits them to dis-
tinguish self from non-self. NK cells are defined by their
capacity to mediate cytotoxicity of cell targets lacking
expression of self MHC, or additional inhibitory ligands.
Activated NK cells can be cytotoxic to autologous oligo-
dendrocytes in vitro (Morse et al., 2001), and are detected in
acute inflammatory CNS lesions (Matsumoto et al., 1998).
However, depletion of NK cells results in increased severity
of EAE, demonstrating their role as regulatory cells
(Takahashi et al., 2001). Thus NK cells, analogous to
CD8 T cells, have both cytotoxic and regulatory potential.
Predicting the net outcome of increasing or decreasing
their numbers or function in autoimmune disease would
be difficult.
Takahashi et al. initially found that peripheral blood of
multiple sclerosis patients in remission had increased pro-
portions of NK cells that expressed high levels of CD95
(Fas), a receptor that can induce apoptosis. Increased Fas/
CD95 expression was not associated with uniform
overexpression of other markers used as indicators of
cell activation. Fas ligand is produced by activated T cells
and microglia/macrophages, raising speculation that this
may be a mechanism contributing to CD95 NK cell apop-
tosis. These NK cells also expressed a profile of non-
inflammatory or Th2 (IL-5) cytokines. These features
were lost during relapse. Takahashi et al. now use an
in vitro approach to show the potential functional relevance
of the CD95þ NK cell subset. Depletion of this subset
from the peripheral blood unmasked the presence of
MBP-reactive T cells in some but not all multiple sclerosis
patients during remission.
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The study raises a number of questions regard-
ing this and other cell populations with regulatory
functions in multiple sclerosis. In the current study,
patients could switch from high to low proportions of
CD95 NK cells or vice versa. MBP-reactive T cells did
not emerge in those who switched from high to low,
although there was a suggestion that such a switch may
be predictive of a pending relapse. In patients with low
CD95 NK proportions but no MBP-reactive cells, other
autoantigens may be involved since regulatory NK cells
are not antigen specific. The current study does not show
directly whether the CD95 NK high group has reduced
immunoreactivity to other antigens. If, as postulated, NK
cells exert their regulatory effect via Th2 cytokines, then
this would represent further justification for immune
deviation direction therapies such as altered peptide
ligands (Kappos et al., 2000) for MS.
The MHC independence of regulatory NK cells is pre-
dicted to be opposite to that of antigen-specific regulatory
T cells. Perhaps NK cells fill a particularly important
regulatory niche in the CNS, a compartment in which
there is relatively low MHC expression. The increased
proportion of CD95 NK high cells during remission
was not linked with increased cytotoxic activity. Cyto-
toxic NK activity is depressed in multiple sclerosis
patients during relapse (Kastrukoff et al., 2003). One
can speculate whether NK regulation and cytotoxicity are
differentially controlled by inhibitory ligands, which them-
selves may be differentially expressed in different tissues
including the CNS.
Overall this paper addresses the important concept that
multiple sclerosis disease in many patients remains poten-
tially chronically active (‘smouldering multiple sclerosis’)
but is held in check by regulatory cells. This raises the
issue as to how current and future therapies impact on these
control mechanisms.
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